Adamantane-Quinoxalone Hybrids: Precision Chemotypes and Their Molecular Mechanisms in Acute Myeloid Leukemia
Authors:
- 31 March 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7693-7706
Abstract
Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis, especially when diagnosed late. Around 10-15% of cases involve the specific chromosomal abnormality t(8;21), which drives uncontrolled myeloid cell proliferation and contributes to disease onset. Despite advances in AML research and treatment protocols, outcomes for t(8;21) AML remain stagnant, as patients receive standard, nonspecific chemotherapies. This one-size-fits-all approach targets both cancerous and healthy cells, leading to unwanted toxicity and highlighting the urgent need for targeted therapies. In this study, we present a precision chemotype based on a quinoxalone-tethered adamantane framework developed via a metal- and light-free protocol. The compound selectively inhibits t(8;21) AML cell proliferation and induces cell death by disrupting growth and metabolic pathways, as demonstrated through bioassays, RNA sequencing, and proteomic analysis. Notably, it spares other leukemic and solid cancer cells, underscoring its specificity and potential as a targeted therapy for t(8;21) AML.Keywords
Funding Information
- Indian Council of Medical Research (NCD/Ad-hoc/223/2022-2)
- Anusandhan National Research Foundation (CRG/2022/004057)
- Human Resource Development Centre, Council of Scientific And Industrial Research (02(0456)21/EMR-II)
- National Institute of Pharmaceutical Education and Research, Ahmedabad
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
- GUJARAT STATE BIOTECHNOLOGY MISSION (GSBTM/JD(R&D)/618/21-22/1222)
This publication has 71 references indexed in Scilit:
- Imidazo[1,2‐ a ]Quinoxaline‐2‐Carbonitrile Derivative (RA‐22) Inhibits Self‐Renewal and Growth of Cancer Stem and Cancer Cells via Downregulating AKT PathwayChemistrySelect, 2024
- Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cellsHemaSphere, 2024
- Molecular medicinal insights into scaffold hopping-based drug discovery successDrug Discovery Today, 2023
- Adamantaniline Derivatives Target ATP5B to Inhibit Translation of Hypoxia Inducible Factor‐1αAdvanced Science, 2023
- Quinoxaline: A comprehension of current pharmacological advancement in medicinal chemistryEuropean Journal of Medicinal Chemistry Reports, 2022
- Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitorsBioorganic Chemistry, 2020
- Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseasesBiochemical and Biophysical Research Communications, 2020
- Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An updateDrug Resistance Updates, 2020
- Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitorsBioorganic & Medicinal Chemistry, 2016
- Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) ProductionEBioMedicine, 2016